Impact of weight loss on obesity-related complications and direct healthcare costs in Japan: A modelling study.

IF 5.4 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Diabetes, Obesity & Metabolism Pub Date : 2025-03-20 DOI:10.1111/dom.16306
Ataru Igarashi, Silvia Capucci, Riku Ota, Shogo Wada, Volker Schnecke
{"title":"Impact of weight loss on obesity-related complications and direct healthcare costs in Japan: A modelling study.","authors":"Ataru Igarashi, Silvia Capucci, Riku Ota, Shogo Wada, Volker Schnecke","doi":"10.1111/dom.16306","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Body mass index (BMI) in Japan has increased over the past decades, leading to corresponding increases in the risks of complications such as type 2 diabetes (T2D). We modelled the impact of weight loss on the incidence of 10 specific complications and resulting healthcare costs in a Japanese cohort.</p><p><strong>Materials and methods: </strong>We adapted our value of weight loss simulation model to represent a cohort of 100,000 Japanese individuals aged 20-69 years with a BMI of 25-50 kg/m<sup>2</sup>. Complication prevalence data were from the Medical Data Vision electronic health record database, and costs were identified using a targeted literature review and the IQVIA claims database. The impact of weight loss was modelled from 2024 to 2029.</p><p><strong>Results: </strong>Total estimated direct medical costs associated with complications were 171.7 million US dollars (USD) or 25.6 billion Japanese yen (JPY) in 2024, projected to increase to 234.9 million USD (35.1 billion JPY) by 2029. A 10% or 15% lower weight across the population was estimated to be associated with a lower incidence of all complications, particularly sleep apnoea, T2D and hypertension. The resulting estimated cumulative cost reductions amounted to 34.6 million USD (5.2 billion JPY) for a 10% weight loss and 47.7 million USD (7.1 billion JPY) for a 15% weight loss over 5 years, largely arising from reductions in T2D.</p><p><strong>Conclusions: </strong>Weight loss in the Japanese population has the potential to drive major reductions in healthcare costs via prevention of complications associated with higher BMI and consequent reductions in costs associated with these complications. Greater weight loss is likely to be associated with greater cost reductions. Our analysis highlights the importance of prompt weight management support for people living with obesity.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dom.16306","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: Body mass index (BMI) in Japan has increased over the past decades, leading to corresponding increases in the risks of complications such as type 2 diabetes (T2D). We modelled the impact of weight loss on the incidence of 10 specific complications and resulting healthcare costs in a Japanese cohort.

Materials and methods: We adapted our value of weight loss simulation model to represent a cohort of 100,000 Japanese individuals aged 20-69 years with a BMI of 25-50 kg/m2. Complication prevalence data were from the Medical Data Vision electronic health record database, and costs were identified using a targeted literature review and the IQVIA claims database. The impact of weight loss was modelled from 2024 to 2029.

Results: Total estimated direct medical costs associated with complications were 171.7 million US dollars (USD) or 25.6 billion Japanese yen (JPY) in 2024, projected to increase to 234.9 million USD (35.1 billion JPY) by 2029. A 10% or 15% lower weight across the population was estimated to be associated with a lower incidence of all complications, particularly sleep apnoea, T2D and hypertension. The resulting estimated cumulative cost reductions amounted to 34.6 million USD (5.2 billion JPY) for a 10% weight loss and 47.7 million USD (7.1 billion JPY) for a 15% weight loss over 5 years, largely arising from reductions in T2D.

Conclusions: Weight loss in the Japanese population has the potential to drive major reductions in healthcare costs via prevention of complications associated with higher BMI and consequent reductions in costs associated with these complications. Greater weight loss is likely to be associated with greater cost reductions. Our analysis highlights the importance of prompt weight management support for people living with obesity.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
Diabetes, Obesity & Metabolism
Diabetes, Obesity & Metabolism 医学-内分泌学与代谢
CiteScore
10.90
自引率
6.90%
发文量
319
审稿时长
3-8 weeks
期刊介绍: Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.
期刊最新文献
A meta-analysis of adverse offspring health outcomes in patients with gestational diabetes mellitus. Comprehensive evaluation of siRNA therapeutics on Lp(a): A network meta-analysis. Efficacy and safety of imeglimin add-on to DPP-4 inhibitor therapy in Japanese patients with type 2 diabetes mellitus: An interim analysis of the randomised, double-blind FAMILIAR trial. FRONTIER: FReeStyle Libre system use in Ontario among people with diabetes in the IC/ES database-Evidence from real-world practice: Patients on basal insulin, glucagon-like peptide 1 receptor agonist or oral therapies. Global, regional and country-specific burden of chronic kidney disease due to type 1 diabetes mellitus: A systematic analysis of the 2021 global disease burden study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1